Post-marketing safety signals of Wilson's disease therapies: evidence from FAERS and VigiBase.
Saved in:
| Title: | Post-marketing safety signals of Wilson's disease therapies: evidence from FAERS and VigiBase. |
|---|---|
| Authors: | Tezel-Yalçın H; Department of Pharmaceutical Toxicology, Faculty of Pharmacy, Hacettepe University, Ankara, Türkiye, 06230, Turkey., Yalçın N; Department of Clinical Pharmacy, Faculty of Pharmacy, Hacettepe University, Ankara, Türkiye, 06230, Turkey. nadir.yalcin@hacettepe.edu.tr., Allegaert K; Clinical Pharmacology and Pharmacotherapy, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, 3000, Belgium.; Department of Development and Regeneration, KU Leuven, Leuven, 3000, Belgium.; Department of Hospital Pharmacy, Erasmus MC, Rotterdam, 3015 GD, The Netherlands., Erkekoğlu P; Department of Pharmaceutical Toxicology, Faculty of Pharmacy, Hacettepe University, Ankara, Türkiye, 06230, Turkey. |
| Source: | Orphanet journal of rare diseases [Orphanet J Rare Dis] 2026 Mar 09; Vol. 21 (1). Date of Electronic Publication: 2026 Mar 09. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: BioMed Central Country of Publication: England NLM ID: 101266602 Publication Model: Electronic Cited Medium: Internet ISSN: 1750-1172 (Electronic) Linking ISSN: 17501172 NLM ISO Abbreviation: Orphanet J Rare Dis Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
